Article
A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal Tumors.
Cancer investigation - 2 Jul 2016
Bendell Johanna C, Bauer Todd M, Lamar Ruth, Joseph Mathew, Penley William, Thompson Dana S, Spigel David R, Owera Rami, Lane Cassie M, Earwood Chris, Burris Howard A
Abstract excerpt
BACKGROUND: AUY922 is an inhibitor of heat shock protein 90 (Hsp90). Hsp90 inhibitors induce kit degradation in preclinical gastrointestinal stromal tumor (GIST) models. This trial was designed to determine the progression-free survival (PFS) of patients with GIST refractory to or intolerant of imatinib and sunitinib. METHODS: Eligible patients received AUY922 70 mg/mg(2) by intravenous (IV) infusion on days 1,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.